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ABSTRACT 
Ayurved system mainly deals with digestion and associated metabolic methods. Liver i.e. Yakrita is the 
Moolasthana of Pachak Pittas, Raktavaha strotasa. Which we can correlate with Hepatobiliary system. 
Disturbance or diseases of hepatic system leads to mortality all the way through failure of remaining 
systems of our body. Kamala is one of the most important and specified disease of Yakrita which can be 
correlated with Hyperbilirubinemia or Jaundice.  
Hyperbilirubinemia is a primary sign of disturbed Liver function. Liver disease is 8th leading cause of death 
worldwide. 50% of patients with Liver cirrhosis and 70% with cirrhosis plus alcoholic hepatitis die within 
48 months. Overall, cirrhosis is the 4th leading cause of death. The overall mortality of acute viral hepatitis 
is 0.5% under the age of 40 yrs. and 3% in patients over 60 yrs. In which mortality rate of HAV and HEV is 
0.5%, HBV is less than 2% and that of HCV is 0.5 -1%. Most of the patients develop chronic infection after 
acute hepatitis which continues for lifetime. Taken as a whole Hepatitis not only disturbs mental, physical 
health of patient but also social, economical, cultural and family life of a person.  
In present study Dhatri Loha Yoga from Ayurvedic granthas tested along with proven efficient drug Kutki 
over Kamala (Hyperbilirubinemia). Dhatri Loha Yoga is a combination of drugs which directly deals with 
bilirubin metabolism. Dhatri LohaYoga significantly reduces symptoms of Kamala upto 94.2 % which is 
very favorable. It shows reduction in Sign, Symptoms, and Specific biochemical markers like SGPT, SGOT, 
and Serum Bilirubin. From the statistical analysis through Chi-square Test the two-sided P value is < 
0.0001, Thus Dhatri loha yoga is extremely significant in the management of Kamala and regulating 
bilirubin metabolism. 
KEYWORDS: Dhatri Loha Yoga, Hyperbilirubinemia, Kamala, Liver function Test. 
INTRODUCTION
Ayurveda (science of life) is one of the branch of 
Vedas. The system has been descended through various 
gods & Rishis who in turn had given it to various scholars 
in the form of Samhita Granthas. In Samhitas it has been 
said that Tridosha - Vata, Pitta & Kapha are the main 
constituent of the body and when they get vitiated they 
causes the disease in our body. According to that one of the 
diseases is described in Samhitas i.e. Kamala which is 
caused by vitiated Pitta dosha.  
 Kamala[1] is one of the prominent conditions 
which attract attention of modern day student of medicine 
as it is seen frequently in various forms today. Though the 
description of disease is not elaborate, basic principles of 
aetiopathology, symptomatology & management are 
described fully in Samhitas. There are two types of Kamala 
described in Charaka samhita Shakhashrita Kamala i.e. 
Aalpapitta Kamala or Rudhaapatha Kamala and 
Koshthashakhashrita Kamala i.e. Bahupitta Kamala.  
According to that Both types of Kamala can be 
correlated with Hyperbilirubinaemia[6] or Jaundice. There 
are many mechanisms which causes Jaundice as follows - 
1. Increased production 2. Impaired excretion 3. 
Hepatocellular Jaundice 4. Cholestasis. As described above 
hepatocellular Jaundice is one of the serious conditions of 
liver diseases. There are so many causes of hepatocellular 
Jaundice, like viral infections, alcohol, drug toxicity, 
obesity, pregnancy. But viral hepatitis & alcoholic hepatitis 
are two major problems in India. The people India are 
living in congested places in bad sanitation, eating 
roadside fast-food, junk foods, drinking polluted water 
that’s why prevalence of viral hepatitis in India is so high.  
The overall mortality of acute viral hepatitis is 
0.5% under the age of 40 yrs. and 3% in patients over 60 
yrs. In which mortality rate of HAV and HEV is 0.5%, HBV 
is less than 2% and that of HCV is 0.5 -1%. Most of the 
patients develop chronic infection after acute hepatitis 
which continues for lifetime. Many patients develop 
cirrhosis & progress to hepatocellular carcinoma. Along 
with viral hepatitis alcoholism and alcoholic liver disorder 
is one of most leading disease in India.  
In modern medical sciences, there is no 
conventional line of treatment regarding hepatitis and 
many modern medicines can damage the liver. At this 
stage Ayurveda can provide suitable treatment for 
jaundice or “Kamala” and with the help of Ayurveda we 
can reduce the duration of illness and prevention of the 
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complications also. Ayurveda has described various drugs 
& preparations for the treatment of “Kamala‟.  
“ Dhatri Loha Yoga[2]”, which having common and 
unique notation part as Phalashruti in different Ayurved 
literatures. Properties of Dhatri Loha Yoga are Pitta, Rakta, 
Mansa shodhana, Yakritagamitva. This is helpful to 
alleviate factors responsible for Samprapti. As drug is 
having property Yakritgamitva it is helpful to alleviate 
Dushti of Moolasthana i.e. Yakrita.  
MATERIALS AND METHODS 
AIMS: 1. To study efficacy of Dhatri Loha Yoga. 
OBJECTIVES 
1. To study the clinical features and details of ‘Kamala’ 
along with hyperbilirubinemia. 
2. To evaluate effect of Dhatri Loha Yoga in Kamala.  
3. To compare the efficacy of Dhatri Loha Yoga in 
Kamala with established drug Kutaki Choorna. 
 The methodology adopted considering to main 
objectives. 40 patients were studied, categorized in two 
groups randomly, with total follow up of 21Days. After 
diagnosis patient were advised to take drug for 21 days. 
Study type- Prospective open randomized study. 
Selection of cases 
 Randomly cases of Kamala, specifically 
Hyperbilirubinemia were selected. Follow-up assessment 
of every patient was done by specially prepared case 
record forms, to meet all baseline requirements. At each 
follow up signs and symptoms were recorded.  
Inclusion criteria – 
Case selection was done as follows- 
Age – 17 to 60 yrs Sex – Both sexes 
Patients – Having raised serum bilirubin (> 3 mg/dl) 
Patients – Having signs and symptoms of Kamala 
uncomplicated patient 
Exclusion criteria – 
- Age below 17 yrs and above 60 yrs 
- Known cases of HIV infection/ AIDS 
-Cases of liver abscess, liver cirrhosis, HBsAg positive 
and known case HIV Positive. 
- Patients having malignancy 
- Patients in acute alcohol withdrawal state, intoxication, 
hepatic encephalopathy 
- Serum bilirubin more than 20 mg/dl 
-Hyperbilirubinaemia due to congenital causes, Drug 
toxicity, AKT. 
- Obstructive pathology 
Drug preparations 
 The drug ‘Dhatri Loha Yoga’ was prepared as per 
reference of Yogaratnakarsamhita[2], Bhaishajya- 
ratnavali[3]. 
Standardization was done in standard pharmacy.  
Dhatri Loha Yoga[4] 
Duration-21 days 
Dose - 5gm twice a day 
Anupana–Madhu, Sharkara and Ghrita in unequal 
quantity. 
Time of administration – During meals in the morning & 
evening (Samana Kala) 
Diet – Specific diet like Khichadi, Mug-dal 
No. of patients – 20 patients 
Kutaki Choorna – Control group 
Duration-21 days 
Dose - 5gm twice a day 
Anupana – Lukewarm water. 
Time of administration – During meals in the morning & 
evening (Samana Kala). 
Follow up - For symptomatic improvement every 7 days 
follow up was done. 
Laboratory follow up was performed weekly in the same 
manner for 3 weeks. 
Case record forms & trial procedure 
 Case record forms (CRF) has been described after 
criteria of diagnosis confirmed, according to our 
requirements containing age, sex, address, economical 
status, place of birth, case registration number etc. 
 - Investigations & systemic examination done along with 
that 
- Symptomatic assessment done on grade scale, severity & 
present/absent.  
 - Ashthavidha, Dashavidha & Strotasaparikshana was done 
according to Ayurveda 
Investigations 
1. Liver Function Test [5, 7] – SGPT (ALT) – weekly, SGOT 
(AST) – weekly, Serum bilirubin level –weekly 
2. Urine for – Bile salt and Bile pigment – weekly 
3. Serum protein, Albumin, Alkaline Phosphate – at the 
start and end of study. 
4. USG Abdomen – at the start of the study 
5. Other investigations – Haemogram, ESR, RFT’s, Lipid 
profile, BSL - at the start and end of the study 
- HIV, VDRL, HBsAg - at the start of the study. 
6. Stool examination – Routine and microscopic was done 
as per requirement 
Parameters of assessment 
1. Overall relief was checked on objective & subjective 
measures.  
Subjective measures were graded in the form of 
mild/moderate/severe. 
2. All signs & symptoms were assessed. 
Subjective assessment 
1. Netra Pitata  
 Absent 0 
 Mild 1 
 Can be seen in Sunlight 2 
 Can be seen without Sunlight also  3 
2. Peet Mutrata  
 Normal urine colour 0 
 Yellowish coloured urine 1 
 Dark yellow coloured urine 2 
 High coloured urine 3 
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Stool colour 
 To evaluate effect on Yellowish Discoloration of 
stool, system adopt as present or absent as visual colour 
assessment faint yellow to too dark brownish yellow 
colour (0-3). Whitish stool colour also considered as grade 
3.  
Objective Assessment 
As stated earlier, the patients of Kamala were 
assessed objectively by laboratory methods on the basis of 
values of liver function tests like SGOT, SGPT, Serum 
Bilirubin (total) and urine examination for the presence/ 
absence of bile salts, bile pigments, on every 7th day of the 
trial. Serum proteins, serum albumin, alkaline phosphatase 
were performed before the start and end of the study. USG 
abdomen was done before the start of the study.  
Urine bile salt & bile pigment can be evaluate as gradation 
3+, 2+, 1, 0.  
Dropouts 
 The patient who did not continue the drug for 3 
weeks were dropped out  
Assessment of drug response  
Overall assessment of drug response was done on 
following basis-  
1. Duration of the disease  
2. Severity of the disease  
3. Effect of overall health during trial of the drug  
4. Clinical response & changes in abnormal laboratory 
findings  
Total effect of Therapy 
 Percentage of relief in symptoms and signs with 
respect to each of the patient will be as follows and will be 
classified as per definition of cured, markedly improved, 
Improved and Unchanged.  
 The criteria described by Thatere A.A. (2003 -04) 
in his P.G.Thesis submitted to Nagpur University is 
considered. 
Cured 
 Complete relief in signs and symptoms along with 
certain laboratory parameters will be considered as cured. 
Markedly Improved 
 50% or more than 50% relief in the signs and 
symptoms of thepatients along with certain definite 
changes in physical and biochemical parameters will be 
considered as markedly improved. 
Improved 
 25% to 50% relief in the signs and symptoms as 
mentioned in the criteria of the assessment will considered 
to be improved. 
Unchanged 
 The patient who doesn’t have any relief in sign, 
symptom and laboratory investigations will be considered 
as unchanged. Along with this the patient exhibiting 
improvement less than 25% will also kept in this category. 
L.A.M.A. 
 Those patients who lefts the treatment before 
advised duration or who didn’t followed instruction about 
the study will be considered as left against medical advice 
(L.A.M.A.). 
OBSERVATION & RESULTS 
After completion of duration 21 days, all the 
patients of this series were explored for investigations, 
which were carried out before the start of treatment. The 
status of all the symptoms & signs were also noted down 
after completion of treatment. Thus the change in the 
status of symptoms, sign & investigations were recorded. 
The history recorded in this study on case record form, 
revealed the facts & findings which are presented herewith 
in the tabular form.  
 
3. Yakrita Vrudhhi  
 Absent 0 
 1 finger 1 
 2 finger 2 
 3 finger ++ 3 
4. Jwara  
 Absent 0 
 Temp.99-100 degree F 1 
 Temp.100-102 degree F 2 
 Temp. above 102 degree F 3 
5. Chhardi (Vomiting)  
 No vomiting 0 
 Less than 3 episodes 1 
 3-6 episodes per day 2 
 More than 6 episodes per day 3 
6. Sadana (Anganam anutsaha)  
 No weakness 0 
 Weakness not disturbing daily routine 
work 
1 
 Weakness disturbing daily routine work 2 
 Weakness required complete bed rest 3 
7. Daha  
 Absent 0 
 Daha tends Trishna (Thirst) 1 
 Daha tends Murcha (Unconsciousness) 2 
 Daha tends Pralapa (Irrelevant talk) 3 
8. Twaka Pitata  
 Absent 0 
 mild 1 
 Can be seen in Sunlight 2 
 Can be seen without Sunlight also 3 
9. Avipaka  
 Normal stool (motions) 0 
 Heaviness in the Abdomen 1 
 Heaviness with sticky/ hard stool 2 
 Heaviness with constipation more than 2 
days 
3 
10. Udarashoola  
 Absent 0 
 Mild 1 
 Moderate 2 
 Severe 3 
11. Aruchi (Anorexia)  
 Normal 0 
 Less desire to eat 1 
 Less desire to eat with nausea 2 
 Less desire to eat with severe nausea 3 
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Table 1- Age wise distribution of patients of Kamala 
Sr. No. Age Group (Yrs) No. of Pt.Trial 
group 
Trial group 
pt. % 
No. of Pt. 
Control group 
Control Group 
pt. % 
1 16 - 35  7 35 % 9 45 % 
2 36 – 45  8 40 % 6 30 % 
3 46- above 5 25 % 5 25 % 
Table 2: Showing Sex wise distribution of patients 
Sr. No. Sex group No. of Pt. 
Trial group 
Trial group pt. 
% 
No. of Pt. 
Control group 
Control Group 
pt. % 
1 Male 12 60 % 15 75 % 
2 Female 8 40 % 5 25 % 
Table 3: Showing Type of food ingested by patients of Kamala 
Sr. No. Type of Diet No. of Pt. 
Trial group 
Trial group 
pt. % 
No. of Pt. 
Control group 
Control Group 
pt. % 
1 Pure Vegetarian 8 40 % 7 35 % 
2 Mixed diet 12 60 % 13 65 % 
Table 4: Showing Type of Vyasana (Addiction) in 40 patients of Kamala 
Sr. No. Type of Addiction No. of Pt. 
Trial group 
Trial group 
pt. % 
No. of Pt. 
Control group 
Control Group 
pt. % 
1 Alcohol+ Smoking/ 
Tobacco 
11 55 % 12 60 % 
2 Tobacco/ Smoking 5 25 % 4 20 % 
3 Tea / coffee 3 15 % 2 10% 
4 Non addicted 1 5 % 2 10% 
Table 5: Showing Habits related to Vihara of patients of Kamala 
Sr. No. Type of Vihara No. of Pt. 
Trial group 
Trial group 
pt. % 
No. of Pt. 
Control group 
Control Group 
pt. % 
1 Prakritanidra 6 30 % 5 25 % 
2 Divaswap 3 15 % 4 20 % 
3 Ratrojagarana 3 15 % 2 10% 
4 Atapasevana 1 5 % 4 20% 
5 Manasikhetu like Chinta, Krodha 7 35% 5 25 % 
Table 6: Showing Doshajaprakriti of patients of Kamala 
Sr. No. Doshajaprakriti No. of Pt. 
Trial group 
Trial group 
pt. % 
No. of Pt. 
Control group 
Control Group 
pt. % 
1 Vatapittaja 6 30 % 8 40 % 
2 Pitta kaphaja 8 40 % 9 45 % 
3 Kaphavataja 6 30 % 3 15 % 
Table 7: Showing Dosha dominance in disease wise distribution of 40 patients of Kamala 
Sr. No. Dosha dominance No. of Pt. 
Trial group 
Trial group pt. 
% 
No. of Pt. 
Control group 
Control Group 
pt. % 
1 Pitta 9 45% 10 50 % 
2 Vaata 8 40 % 5 25 % 
3 Kapha 3 15% 5 25 % 
Table 8: Showing Agni-Parikshana of 40 patients of Kamala 
Sr. No. Agni No. of Pt. 
Trial group 
Trial group pt. 
% 
No. of Pt. 
Control group 
Control Group 
pt. % 
1 Tikshana 7 35% 7 35 % 
2 Vishama 8 40 % 9 45 % 
3 Mandagni 5 25% 4 20 % 
Subjective assessment  
The patients suffering from Kamala which was included in the trial had to undergo clinical examination at every 
follow up for clinical assessment of the improvement in signs & symptoms. 
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Table 9: Showing effect of therapy on symptoms: Trial group  
Symptoms BT 
(Before Treatment) 
AT 
(After Treatment) 
Difference Percentage of relief 
NetraPeetata 56 1 55 98% 
Peetamutrata 49 1 48 97% 
Yakritavruddhi 30 3 27 88% 
Jvara 11 3 8 85% 
Chhardi 17 1 16 95% 
Sadana 37 2 35 94% 
Daha 20 1 19 95% 
TwakaPeetata 56 1 55 97% 
Avipaka 17 1 16 95% 
Udarshoola 40 2 38 95% 
Aruchi 56 1 55 97% 
Avarage 35.36 1.54 33.81 94.2% 
Table 10 : Showing effect of therapy on symptoms: Control group  
Symptoms BT AT Difference Percentage of relief 
NetraPeetata 44 6 38 80% 
Peetamutrata 47 2 45 93% 
Yakritavruddhi 18 2 16 60% 
Jvara 16 2 14 63% 
Chhardi 33 8 25 63% 
Sadana 43 10 33 76% 
Daha 33 4 29 75% 
TwakaPeetata 44 4 36 77% 
Avipaka 32 4 28 81% 
Udarshoola 47 4 43 91% 
Aruchi 46 6 40 90% 
Avarage 36.63636 4.727273 31.54545 75.20% 
Table 11: Wilcoxon match paired sign rank test : Trial group 
No. Symptoms Mean SD SEd W N Z p 
1 NetraPeetata 
BT & AT Diff. 
 
2.75 
 
0.53 
 
0.119 
 
210 
 
20 
 
3.92 
 
<0.001 
2 Peetamutrata 
BT & AT Diff 
 
2.4 
 
0.66 
 
0.032 
 
210 
 
20 
 
3.92 
 
<0.001 
3 Yakritavruddhi 
BT & AT Diff 
 
1.35 
 
0.72 
 
0.162 
 
171 
 
18 
 
3.72 
 
<0.001 
4 Jwara 
BT & AT Diff 
 
0.4 
 
0.73 
 
0.164 
 
29 
 
8 
 
2.03 
 
<0.05 
5 Chhardi 
BT & AT Diff 
 
0.81 
 
0.87 
 
0.19 
 
66 
 
11 
 
2.93 
 
<0.05 
6 Sadana 
BT & AT Diff 
 
1.75 
 
0.82 
 
0.185 
 
190 
 
19 
 
3.82 
 
<0.001 
7 Daha 
BT & AT Diff. 
 
0.95 
 
0.58 
 
0.131 
 
136 
 
16 
 
3.51 
 
<0.001 
8 TwakaPeetata 
BT & AT Diff 
 
2.75 
 
0.43 
 
0.096 
 
210 
 
20 
 
3.92 
 
<0.001 
9 Avipaka 
BT & AT Diff 
 
0.8 
 
0.87 
 
0.194 
 
66 
 
11 
 
2.93 
 
<0.05 
10 Udarashoola 
BT & AT Diff 
 
1.9 
 
0.83 
 
0.185 
 
190 
 
19 
 
3.82 
 
<0.001 
11 Aruchi 
BT & AT Diff 
 
2.75 
 
0.43 
 
0.09 
 
210 
 
20 
 
3.92 
 
<0.001 
Table 12: Wilcoxon match paired sign rank test : Control group 
No. Symptoms Mean SD SEd W N Z p 
1 NetraPeetata 
BT & AT Diff 
 
1.9 
 
0.99 
 
0.222 
 
171 
 
18 
 
3.72 
 
<0.001 
2 Peetamutrata 
BT & AT Diff 
 
2.25 
 
0.88 
 
0.198 
 
190 
 
19 
 
3.82 
 
<0.001 
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3 Yakritavruddhi 
BT & AT Diff. 
 
0.8 
 
0.74 
 
0.167 
 
78 
 
12 
 
3.06 
 
<0.05 
4 Jwara 
BT & AT Diff 
 
0.7 
 
0.71 
 
0.159 
 
92 
 
14 
 
2.88 
 
<0.001 
5 Chhardi 
BT & AT Diff 
 
1.25 
 
0.94 
 
0.21 
 
144 
 
17 
 
3.40 
 
<0.001 
6 Sadana 
BT & AT Diff 
 
1.65 
 
0.79 
 
0.177 
 
171 
 
18 
 
3.72 
 
<0.001 
7 Daha 
BT & AT Diff 
 
1.45 
 
1.02 
 
0.228 
 
136 
 
16 
 
3.51 
 
<0.001 
8 TwakaPeetata 
BT & AT Diff 
 
1.8 
 
0.92 
 
0.20 
 
171 
 
18 
 
3.72 
 
<0.001 
9 Avipaka 
BT & AT Diff 
 
1.4 
 
1.15 
 
0.258 
 
91 
 
13 
 
3.18 
 
<0.05 
10 Udarashoola 
BT & AT Diff 
 
2.15 
 
0.79 
 
0.177 
 
210 
 
20 
 
3.92 
 
<0.001 
11 Aruchi 
BT & AT Diff 
 
2.0 
 
0.77 
 
0.173 
 
210 
 
20 
 
3.92 
 
<0.001 
To study the significance between symptomatic relief in trial and control group evaluated as-  
Table 13: Mann-whitnys test 
 
R U Mean U SD (U) Z p 
 
NetraPeetata 401 169 180 34.2 0.3 0.0075 Very significant 
Peetamutrata 324 161 190 35.59 0.8 0.7736 Not significant 
Yakritavruddhi 239 148 108 23.62 1.67 0.0449 Significant 
Jwara 65 83 56 14.65 1.8 0.1676 Not significant 
Chhardi 106 180 93.5 21.25 4.04 0.1024 Not significant 
Sadana 294 238 171 32.9 2.02 0.8268 Not significant 
Daha 157 235 128 26.53 4.01 0.1447 Not significant 
Twakapeetata 430 140 180 34.2 1.15 0.0014 Very significant 
Avipaka 141 73.5 84.5 19.5 0.5 0.9891 Not significant 
Udarshool 295 275 190 35.59 2.37 0.4052 Not significant 
Aruchi 450 160 200 36.96 1.06 0.0044 Very significant 
OBJECTIVE ASSESSMENT 
Table 14: Showing effect of therapy on Hb% in 20 patients of Kamala of Trial group by Dhatri loha yoga And 
20 patients of control group with Kutaki Choorna 
Objective criteria Mean ± SD Mean of difference ± SD SED  t value  p value  
BT  AT 
Trial group HB %  11.62 ± 2.05  13.03 ± 1.48  1.405± 1.28  0.288  4.87  < 0.001 
Control group HB %  11.42 ± 1.78 11.47 ± 1.65 0.045± 0.2924 0.065 0.688 > 0.05 
Table 15: Showing effect of therapy on RBC, WBC in 20 patients of Kamala of Trial group by Dhatriloha yoga 
And 20 patients with Kutaki Choorna 
Objective criteria Mean ± SD Mean of difference ± 
SD 
SED  t value  p value  
BT  AT 
Trial group RBC  4.415 ± 1.22 4.98 ± 0.871  0.565± 0.493  0.1103  5.12  < 0.001 
Control group RBC  4.085 ± 1.19  4.18 ± 1.112  0.095± 0.1883 0.0421  2.255  > 0.05 
Trial group WBC  6500±2408.1 6490± 2044.2  10± 824.56  184.38  0.0542  >0.05 
Control group WBC  6020± 613.9  6175± 1563.3  155± 785.16 175.57  0.88  > 0.05 
Table 16: Showing effect of therapy on Cholesterol, Triglycerides, HDL, LDL, in 20 patients of Kamala of Trial 
group by Dhatriloha yoga And 20 patients with Kutaki choorna 
Objective criteria Mean ± SD Mean of 
difference ± SD 
SED  t value  p value  
BT  AT 
Trial group - Total 
cholesterol 
199.7 ± 37.32 176.3 ± 28.08  23.4 ± 28.93 6.47  3.6166  < 0.001 
Control group Total 
cholesterol 
238.8 ± 34.80 228.8 ± 30.25 9.95 ± 15.419 3.4478 2.8859 <0.001 
Trial group 
Triglycerides 
182.3 ± 40.44 165.9 ± 38.74  16.4 ± 27.359 6.1178  2.6807  < 0.05 
Trial group HDL 44.65±. 9772 45 ± 7.1274  0.35 ±4.72 1.0566  0.33  > 0.05 
Trial group LDL 124.5± 7.979 118.35±16.05 6.15 ± 13.101 2.9294 2.0994 >0.05 
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Control group 
Triglycerides 
190.9 ± 33.323  183.05 ± 28.895  7.85 ± 16.841 3.7658 2.0845 >0.05 
Control group HDL 47.15 ± 7.95 45.8 ± 7.39 1.35 ± 4.0654 0.9091 1.4851 >0.05 
Control group LDL 135.75 ± 
19.015 
131.55 ± 19.067 4.2 ± 9.6778 2.164 1.9408 >0.05 
Table 17: Showing effect of therapy on S. Protein, Albumin, S. Alkaline Phosphate in 20 patients of Kamala of 
Trial group by Dhatri Loha Yoga And 20 patients with Kutaki Choorna 
Objective criteria –
Trial group 
Mean ± SD Mean of 
difference ± SD 
SED  t value  p value  
BT AT 
S. Protein 6.395 ± 1.256 6.231 ± 0.9959 0.182 ± 0.6296 0.1408 1.2929 >0.05 
S.Albumin 4.465 ± 1.026 4.835 ± 1.1016 0.37 ±1.0664 0.2385 1.552 >0.05 
S.Alkaline phosphate 92.1 ± 24.959 87.4 ± 21.397 4.7 ± 8.82 1.9738 2.3812 < 0.05 
Objective criteria-  
Control group  
Mean ± SD Mean of 
difference ± SD 
SED  t value  p value  
BT  AT 
S. Protine 6.43± 1.251  6.23± 1.005  0.2 ± 0.6249 0.139 1.431 >0.05 
S. Albumin 4.62± 0.989 4.805± 1.092 0.185 ± 1.1068 0.247 0.747  > 0.05 
S.Alkaline phosphate 76.± 20.70 78.7± 14.66 2.65 ± 16.045 3.587 0.739 > 0.05 
Table 18 : Showing effect of therapy on SGPT in 20 patients of Kamala of Trial group by Dhatri Loha Yoga 
And 20 patients with Kutaki Choorna with follow up at 7th, 14th and at end 21th day 
SGPT  Trial group Control group 
Mean ± SD  BT 343.5 ±278.24 236.55±212 
 After 7 days 272.2 ±213.93 182.1±152.7 
Mean of difference ± SD  71±79.057 54.45±77.319 
t value  4.016 3.1494 
p value  <0.001 <0.01 
 
SGPT  Trial group Control group 
Mean ± SD  BT 343.5 ±278.24 236.55±212 
 After14days 128.75±63.515 151.35 ±95.322 
Mean of difference ± SD  214.75±235.22 85.2±128.28 
t value  4.0828 2.97 
p value  <0.001 <0.01 
 
SGPT  Trial group Control group 
Mean ± SD  BT 343.5 ±278.24 236.55±212 
 AT -21 days 43.8±22.409 101.05±48.16 
Mean of difference ± SD  299.7±260.18 135.5±192.22 
t value  5.1513 3.1525 
p value  <0.001 <0.01 
Table 19 : Showing effect of therapy on SGOT in 20 patients of Dhatri Loha Yoga of Trial group by Dhatri 
Loha Yoga And 20 patients with Kutaki Choorna with follow up at 7th, 14th and at end 21th day 
SGOT  Trial group Control group 
Mean ± SD  BT 346.15 ±267.28 235.05±185.27 
 After7days 266.35 ±231.79 180.9±118.25 
Mean of difference ± SD  79.8±67.763 54.15±74.418 
t value  5.2665 3.25 
p value  <0.001 <0.01 
 
SGOT  Trial group Control group 
Mean ± SD  BT 346.15 ±267.28 235.05±185.27 
 After14days 122.15±76.542 154.9 ±96.079 
Mean of difference ± SD  224±205.58 80.15±99.88 
t value  4.8728 3.5887 
p value  <0.001 <0.01 
 
SGOT  Trial group Control group 
Mean ± SD  BT 346.15 ±267.28 235.05±185.27 
 AT21days 61±29.452 119.55±49.497 
Mean of difference ± SD  285.15±248.02 115.5±146.14 
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t value  5.1417 3.5345 
p value  <0.001 <0.01 
Table 20: Showing effect of therapy on Total Bilirubin in 20 patients of Kamala of Trial group by Dhatri 
Loha Yoga And 20 patients with Kutaki Choorna with follow up at 7th, 14th and at end 21th day 
Bilirubin  Trial group Control group 
Mean ± SD  BT 9.28±3.602 7.465±3.92 
 After 7 days 4.365 ±2.7002 5.475±2.511 
Mean of difference ± SD  4.915±1.8062 1.99±1.734 
t value  12.17 5.1322 
p value  <0.0001 <0.001 
 
Bilirubin  Trial group Control group 
Mean ± SD  BT 9.28±3.602 7.465±3.92 
 After 14 days 1.785±1.10 3.64 ±2.2087 
Mean of difference ± SD  7.494±3.0179 3.825±2.2669 
t value  11.107 7.5459 
p value  <0.0001 <0.001 
 
Bilirubin  Trial group Control group 
Mean ± SD  BT 9.28±3.602 7.465±3.92 
 AT 21 days 1.02±0.5537 1.965±1.185 
Mean of difference ± SD  8.26±3.393 5.5±3.2633 
t value  10.887 7.5374 
p value  <0.0001 <0.001 
Table 21: Showing effect of therapy on Urine Bile salt, Bile pigment in 20 patients of Kamala of Trial group by 
Dhatri Loha Yoga And 20 patients with Kutaki Choorna 
Objective criteria  
–Trial group 
Mean ± SD 
BT               AT 
Mean of 
difference ± SD 
SED  t value  p value  
Bile salt 3 ± 0 0.05 ±0.217 2.95 ± 0.217 0.047 60.53 > 0.0001 
Bile pigment 3 ± 0 0.05 ±0.217  2.95 ± 0.217 0.047  60.53  > 0.0001 
Control group      
Bile salt 3 ± 0 0.25± 0.433 2.75 ± 0.433 0.0968 28.402 >0.001 
Bile pigment 3 ± 0 0.25± 0.433 2.75 ± 0.433 0.0968 28.402  >0.001 
Table 22: Showing effect of therapy on stool colourin patients of Kamala of Trial group by Dhatri Loha Yoga 
and patients with Kutaki Choorna 
Objective criteria–Trial 
group 
Mean ± SD 
BT               AT 
Mean of difference 
± SD 
SED  t  
value  
p value  
Stool colour 3 ± 0 0.05 ± 0.2179  2.95 ± 0.2179 0.048  59  < 0.001 
Control group.  
Stool colour 
3 ± 0  0.25 ± 0.433  2.75 ± 0.433 0.096 27.68 <0.001 
Table 23: Group I Trial group -Total effect of therapy on patients, having 21days follows up according to 
subjective & objective assessment 
No. patient  % of relief in symptoms  % of relief in signs  Average %  Remark  
1  100% 13.19497 56 Markedly improved  
2  100% 19.25751 59.629 Markedly improved  
3  94% 18.83454 56.4175 Markedly improved  
4  77% 28.02904 52.5 Markedly improved  
5  91% 23.48296 57.24 Markedly improved  
6  94% 21.58152 57.791 Markedly improved  
7  100% 24.60557 62.303 Markedly improved  
8  82% 18.08887 49.0445 Improved  
9  85% 19.39101 52.1955 Markedly improved  
10  100% 26.49482 63.18 Markedly improved  
11  94% 26.36656 60.18 Markedly improved  
12  100% 27.0354 63.515 Markedly improved  
13  91% 20.26309 55.6315 Markedly improved  
14  100% 25.60537 62.8025 Markedly improved  
15  95% 22.14254 58.57 Markedly improved  
16  95% 21.36425 58.18 Markedly improved  
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17  100% 21.7997 60.9 Markedly improved  
18 100% 25.20772 62.604 Markedly improved  
19 91% 26.98678 58.9935 Markedly improved  
20 100% 27.81322 63.9065 Markedly improved  
Table 24: Group 2 Control group -Total effect of therapy on patients, having 21days follows up according to 
subjective & objective assessment 
No. patient  % of relief in symptoms  % of relief in signs  Average %  Remark  
1  78.78788 8.73627 43.76207 Improved 
2  84.84848 12.6297 48.73909 Improved 
3  87.87879 15.19955 51.53917 Markedly improved 
4  78.78788 10.00844 44.39816 Improved 
5  77.27273 13.85844 45.56558 Improved 
6  100 13.30869 56.65435 Markedly improved 
7  74.24242 17.8103 46.02636 Improved 
8  72.72727 17.06195 44.89461 Improved 
9  81.81818 18.79199 50.30509 Markedly improved 
10  81.81818 17.52801 49.6731 Improved 
11  90.90909 19.48255 55.19582 Markedly improved 
12  51.51515 26.30229 38.90872 Improved 
13  81.81818 16.4569 49.13754 Improved 
14  86.36364 18.85166 52.60765 Markedly improved 
15  63.63636 15.30176 39.46906 Improved 
16  68.18182 22.61787 45.39984 Improved 
17  74.24242 17.59552 45.91897 Improved 
18 63.63636 11.84175 37.73905 Improved 
19 45.45455 13.18858 29.32156 Improved 
20 60.60606 14.16061 37.38334 Improved 
Table 25: Chi square Test 
  Cured Markedly improved Improved Uncured Total 
Trial group 0 1 (48%) 1 (3%) 0 20 
Control group 0 5 (13%) 15 (38%) 0 20 
Total 0 24 (60%) 16 (40%) 0 40 
Chi-square Test  
For the above data value of x2 = 19.2 
The two-sided P value is < 0.0001, considered extremely 
significant. 
The row/column association is statistically significant. 
Thus Trial group is extremely significant than control 
group. 
Total effect of therapy  
With the consideration of gradation as cured, 
improved, markedly improved, uncured we found due to 
effect of Dhatri Loha Yoga 19 patients having marked 
improvement which is about 95 % and rest 5% have 
improved results. As compared to above Kutaki Choorna 
gives marked improvement in 25 % patients and 75 % had 
results as improved. 
  There difference of significance calculated with 
Chi square test, and results found as highly significant.  
 It means Role of Dhatri Loha Yoga is very highly 
significant than Kutaki choorna for reduction of Sign, 
Symptoms, and Specific biochemical markers like SGPT, 
SGOT, and Serum Bilirubin. 
 It shows that, Dhatri Loha Yoga is one of the 
effective remedy for treatment of Kamala  (Hyper-
bilirubinaemia).  
 Kamala is one gravies problem in the world, 
because of which patient is always in trouble. This initial 
study is toddler step forward for further study to find 
satisfactory solution.  
CONCLUSION 
 Clinical evaluation of Dhatri Loha Yoga in Kamala 
was completed in 40 patients. In Trial group of 20 treated 
with Dhatri Loha Yoga and 20 patients in control group 
treated with Kutaki Choorna. Conclusion drawn according 
to observation and results are given here: 
1. Most of the patients were from Middle class income 
group and were educated. 
2. Maximum patients having the habit of diet of Katu 
Rasa. Then Amla, Lavana rasa dominance was also 
observed. 
3. Majority of patients having history of mixed diet. 
4. Most of patients having Vyasana such as Alcohol, 
smoking, Tobacco etc. tea coffee addiction was next to 
them. 
5. Maximum patients having history of Ratrijagarana, 
Diwaswap.  
6. Manasikahetu –From total sample in 30% of patient’s 
Mansikahetu like stress, anxiety was observed.  
 So we conclude  that, Middle economic class, 
indulgence of Katu, Lavana, Amla rasa; history of addiction, 
Non-veg consumption, habit of Ratrijagarana, Diwaswapa, 
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psychological factors like stress, anxiety were observed as 
main causative factors for Kamala.  
1. Percentage of Kamala was observed more in Vata-
Pittaja prakriti. 
2. Percentage of Kamala was observed more in 
Pittajadosha dominant. 
3. Evidence of Kamala was very much seen in patients 
having Tikshna & Mandagni. 
4. Conclusion of symptoms as per scoring system in 
patients of Kamala- Dhatri Loha Yoga significantly 
reduces symptoms upto 94.2 % which is very 
beneficial As compared Kutaki Choorna which 
reduces symptoms to 75.2 %. Wilcoxon test applied 
to effect of therapy on symptoms of both groups was 
found highly significant. Mann Whitney test applied 
for testing significance of difference between trial 
and control group which found significant. 
5. Conclusion of Biochemical markers as per scoring 
system in patients of Kamala. After applying paired t 
test for biochemical markers we found Dhatri Loha 
Yoga reduces Cholesterol, LDL, Triglycerides, 
S.Alkalinephosphate; which was not reduced by 
Kutaki Choorna in control group patients. Due to 
presence of Lohabhasma is Dhatri Loha Yoga it 
increases Hb %, RBC level. Rest of all markers had no 
significant changes. 
6. Conclusion of SGOT, SGPT, S. Bilirubin as per scoring 
system in patients of Kamala. After examining 
patients each after 7 days for total 21 days we found 
both Kutaki Choorna and Dhatri loha yoga reduces 
SGPT, SGOT & S. Bilirubin level significantly. This was 
evaluated by paired t test. After calculating 
significance of difference between trial and control 
group with the help of unpaired t test we found 
Dhatri Loha Yoga is highly significant in decreasing 
bilirubin, SGPT and SGOT levels.  
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